InvestorWire NewsRoom


InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Appoints Diabetes, Behavioral Health Experts to Scientific Advisory Board
January 13, 2021

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Appoints Diabetes, Behavioral Health Experts to Scientific Advisory Board

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced the appointment of two renowned experts to its Scientific Advisory Board (“SAB”). Dr. Marilyn Ritholz, psychologist at Joslin Diabetes Center, a Harvard Medical School affiliate, and Dr. David Horwitz, former global chief medical officer of Johnson & Johnson Diabetes Institute, join SAB chairman Eric Milledge; the prestigious board is focused on advancing Dario’s technical leadership, helping to guide the development of the company’s bold technology road map and advancing Dario’s DTx (“DTx”) platform by integrating members’ comprehensive experience and expertise into the company offering. Ritholz and Horwitz are recognized as experts in the fields of diabetes, metabolism, and behavioral health. A senior psychologist at the Joslin Diabetes Center, Ritholz is also on the faculty at Beth Israel Deaconess Medical Center (“BIDMC”) and is an assistant professor of psychology at Harvard Medical School. A senior consultant with Numerof & Associates, Horwitz also serves as president of DLH Biomedical Consulting and has previously held faculty positions in the medical schools at the University of Chicago and the University of Illinois. “My objective is to populate Dario’s SAB with renowned members of the global medical community who align with Dario’s approach to empower individuals to achieve meaningful, sustainable behavior change through highly personalized, AI-driven experiences that adapt dynamically through a member’s journey,” said Milledge in the press release. “Dr. Ritholz’s accomplishments at the Joslin Diabetes Center, a Harvard Medical School affiliate, include a leading practice focused on the intersection of psychology and diabetes management in adolescents and adults. Her expertise will be key in refining aspects of our technology for improved patient-provider interactions and, ultimately, better care. Dr. Horwitz’s experiences as a Board-Certified internist and endocrinologist, coupled with his knowledge of the healthcare ecosystem, will lay the foundation for a strong board committed to improving patient care. I am excited to work with them as we continue to build out the SAB and drive continued innovation of Dario’s platform.”

To view the full press release, visit

About DarioHealth Corp.

DarioHealth Corp. is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. By delivering evidence-based interventions driven by connected devices, data, high-quality software and coaching, the company makes the right thing to do the easy thing to do. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The highly engaging, user-centric MyDario(TM) mobile app is used regularly by tens of thousands of consumers worldwide. The company is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).